Despite this, investors seem to have made up their one-track mind. Eli Lilly’s P/E ratio is more than double that of Novo ...

Britain will study whether the use of Eli Lilly's weight loss drug can get people back into work and help tackle the high ...

Blockbuster diabetes and weight loss drugs, known as GLP-1 treatments, could help reduced the rate of overdoses and ...

The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

Two companies — Eli Lilly and Novo Nordisk — dominate the weight-loss drug market and their stocks have surged in the recent ...

Earlier this year, J.P. Morgan released a report outlining the potential for GLP-1 treatments in other markets. Specifically, ...

In a huge new study, researchers have found evidence that drugs like Ozempic can help with alcohol and opioid addiction.

Judge Karen Marston held that, despite plaintiffs' arguments to the contrary, marketing discovery is not relevant to the ...

Revolutionary weight management and diabetes medications could prove to be the next frontier in addiction recovery treatment medications.

"These are not case-specific issues," the plaintiffs contended. "The marketing was national in scale and magnitude, and ...

Eli Lilly shares have soared thanks to excitement about the company's position in the weight loss drug market.